Hong Kong IPO: WuXi Biologics unit eyes up to US$520 million in biotech push WuXi XDC, a 60 per cent-owned unit of WuXi Biologics, could raise as much as US$520 million, including excess share ...
Wuxi Biologics (Cayman), Inc. is an investment holding company, which engages in the discovery, development and manufacture of biologics services. Its services include testing; clinical drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback